

Specimen Collected: 17-Jun-24 14:10**HBV Quant with Reflex to HBV Genotype** | Received: 17-Jun-24 14:13 | Report/Verified: 17-Jun-24 14:19

Procedure	Result	Units	Reference Interval
HBV Qnt by NAAT (IU/mL)	6,000,000	IU/mL	
HBV Qnt by NAAT (log IU/mL)	6.78 ^{f1}	log IU/mL	
HBV Qnt by NAAT Interp	Detected * i1		[Not Detected]

HBV Genotype by Sequencing | Received: 17-Jun-24 14:13 | Report/Verified: 18-Jun-24 10:06

Procedure	Result	Units	Reference Interval
Hepatitis B Genotype by Seq	Type A		
HBV Surface Antigen Mutations by Seq	Detected ^{f2}		
HBV RT Polymerase Mutations by Seq	Detected ^{f3 i2}		

Result Footnote

f1: HBV Qnt by NAAT (log IU/mL)

Hepatitis B Virus Genotype by Sequencing will be added.

f2: HBV Surface Antigen Mutations by Seq

The following HBV surface antigen mutations were detected: P127S

f3: HBV RT Polymerase Mutations by Seq

The following resistance associated HBV RT polymerase mutations were detected: A181T

Resistance interpretation:

Lamivudine: Reduced Sensitivity

Telbivudine: Reduced Sensitivity

Entecavir: Sensitive

Adefovir: Resistant

Tenofovir: Reduced Sensitivity

Test Information

i1: HBV Qnt by NAAT Interp

INTERPRETIVE INFORMATION: HBV by Quantitative NAAT

The quantitative range of this test is 1.00-9.00 log IU/mL (10-1,000,000,000 IU/mL).

An interpretation of "Not Detected" does not rule out the presence of inhibitors in the patient specimen or HBV DNA concentration below the level of detection of the test. Care should be taken when interpreting any single viral load determination.

This test is intended for use as an aid in the management of patients with chronic HBV infection undergoing anti-viral therapy. The test can be used to measure HBV DNA

* = Abnormal, # = Corrected, C = Critical, f = Result Footnote, H = High, i = Test Information, L = Low, t = Interpretive Text, @ = Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 24-169-900106**Report Request ID:** 19476901**Printed:** 18-Jun-24 10:08

Page 1 of 2

Test Information

i1: HBV Qnt by NAAT Interp
levels at baseline and during treatment to aid in assessing response to treatment. Results must be interpreted within the context of all relevant clinical and laboratory findings.

This assay should not be used for blood donor screening, associated reentry protocols, or for screening human cell, tissues, and cellular tissue-based products (HCT/P).

i2: HBV RT Polymerase Mutations by Seq
INTERPRETIVE INFORMATION: HBV Genotype by Sequencing

Both the HBV RT polymerase and the HBsAg encoding regions are sequenced. Resistance and surface antigen mutations are reported. In addition, the major HBV genotypes are identified. Mutations in viral sub-populations below 20 percent of total may not be detected.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 24-169-900106

Report Request ID: 19476901

Printed: 18-Jun-24 10:08